|1.||Sakagami, Masafumi: 5 articles (08/2014 - 11/2005)|
|2.||Inokuchi, Akira: 4 articles (08/2014 - 11/2005)|
|3.||Kurono, Yuichi: 4 articles (08/2014 - 11/2005)|
|4.||Aiba, Tsunemasa: 4 articles (08/2014 - 11/2005)|
|5.||Ikeda, Minoru: 4 articles (08/2014 - 11/2005)|
|6.||Takeda, Noriaki: 4 articles (08/2014 - 11/2005)|
|7.||Itoh, Yoshinori: 3 articles (01/2015 - 10/2010)|
|8.||Takei, Mineo: 3 articles (01/2012 - 01/2006)|
|9.||Handa, Osamu: 3 articles (11/2011 - 11/2002)|
|10.||Yoshikawa, Toshikazu: 3 articles (11/2011 - 11/2002)|
|1.||Taste Disorders (Taste Disorder)
01/01/2012 - "In this review, we primarily make reference to our own data on the pharmacological action of polaprezinc on taste disorders and introduce recent research on the effects of polaprezinc in treating other diseases."
01/01/2012 - "The pharmacological action of polaprezinc, however, on taste disorders remains unclear. "
10/01/2009 - "A zinc-containing compound, Polaprezinc, is effective for patients with taste disorders: randomized, double-blind, placebo-controlled, multi-center study."
04/01/2011 - "Orally disintegrating tablets of polaprezinc were then administered to the patient, after which the subjective symptom of taste disorder improved. "
08/01/2014 - "The present study investigated the time course of changes in disc gustometry results and subjective symptom scores measured at 4-week intervals in 44 patients with a taste disorder who were considered eligible for zinc replacement treatment and who received polaprezinc at a dose of 150 mg/day (equivalent to a 34 mg/day dose of zinc) for up to 24 weeks. "
01/01/1997 - "These results suggest that Z-103 is as effective against TNB-induced colitis as SASP."
10/14/2006 - "Polaprezinc is a useful therapeutic agent for treatment of colitis and its effects depend on the function of cytoprotective HSP in colon."
11/01/2005 - "Polaprezinc suppresses DSS-induced colitis in mice, partly through inhibition of production of pro-inflammatory cytokine, suppression of neutrophils accumulation and cytoprotection by overexpression of HSPs. "
11/01/2005 - "DAI and histological scores were remarkably reduced in polaprezinc-treated mice with DSS-induced colitis. "
01/01/1997 - "Effect of Z-103 on TNB-induced colitis in rats."
|3.||Stomach Ulcer (Gastric Ulcer)
05/01/1992 - "[Studies on the healing promoting action of Z-103 in chronic gastric ulcer models of rats]."
01/01/2001 - "Repeated administration of polaprezinc accelerated the healing of gastric ulcers in both normal and arthritic rats, in a dose-dependent manner, and this effect was more pronounced in arthritic rats. "
02/01/1999 - "Polaprezinc has been shown to exert an anti-oxidant property in a tube experiment, protect gastric mucosa from experimental ulcerations in vivo, and accelerate the healing of gastric ulcer in humans. "
04/01/1990 - "These results suggest that Z-103 may be a new therapeutic agent sharing both healing-promoting and relapse-preventive actions on gastric ulcers."
05/01/2010 - "To clarify the incidence of ulcer base protrusion in ulcers induced by endoscopic submucosal dissection (ESD), and whether the addition of polaprezinc, a cytoprotective agent used for treatment of gastric ulcer, to the PPI regimen helps to suppress it. "
01/01/2013 - "The median number of reddened lesions and erosions/ulcers upon follow-up CE in the polaprezinc group significantly decreased (P < 0.05). "
12/01/2010 - "Rhizoma Zingiber officinale (ginger) extract (1.5-5 g/kg) or polaprezinc (30 and 60 mg/kg) was orally given to the animals once daily for three consecutive days after ulcer induction. "
05/01/2010 - "Polaprezinc prevents protrusion of the ulcer base during the healing of ESD-induced ulcer with PPI."
05/01/2010 - "Polaprezinc was the only significant factor (p = 0.0001) differentiating patients who had ulcer base protrusion (n = 17) from those who did not (n = 137). "
07/01/2009 - "We tested a possibility that polaprezinc (PZ), an anti-ulcer drug, could induce HO-1 in the gastric mucosa. "
|5.||Peptic Ulcer (Peptic Ulcers)
01/01/1995 - "Toxicity of the novel anti-peptic ulcer agent polaprezinc in beagle dogs."
10/01/2010 - "Compounds containing zinc, such as polaprezinc, were developed in Japan and used as an antiulcer drugs in the treatment of human peptic ulcer disease. "
11/01/2005 - "Most doctors (70%) prescribed polaprezinc, a zinc-containing drug that is used to treat peptic ulcers. "
11/14/1991 - "The antioxidant properties of a novel anti-peptic ulcer agent Z-103 in vitro were compared with those of zinc ion and L-carnosine. "
01/01/1999 - "Fifty-nine patients with Hp-positive peptic ulcer disease were treated with a combination of amoxicillin, clarithromycin, lansoprazol, and polaprezinc Subsequently, erosive duodenitis developed in 18 (43.2%) of 44 patients in whom Hp was eradicated successfully. "
|9.||polaprezinc (Z 103)
|10.||Acetic Acid (Vinegar)
|1.||Drug Therapy (Chemotherapy)
|2.||Renal Dialysis (Hemodialysis)
|5.||Hematopoietic Stem Cell Transplantation